Showing 1711-1720 of 7669 results for "".
- Do Physicians Mention Sunscreen Use Often Enough at Patient Visits?https://practicaldermatology.com/news/20130905-do_physicians_mention_sunscreen_use_often_enough_at_patient_visits/2459468/A recent JAMA Dermatology study found that physicians mention sunscreen at a low rate during patient visits, even to patients with a history of skin cancer. Researchers used the National Ambulatory Medical Care Survey to identify patient visits to nonfederal outpatient physic…
- Sensus Healthcare Appoints Dr. Mark Nestor as Clinical Directorhttps://practicaldermatology.com/news/20130830-sensus_healthcare_appoints_dr_mark_nestor_as_clinical_director/2459470/Mark Nestor, MD, PhD has been appointed as Clinical Director of Sensus Healthcare. Dr. Nestor will lead the company's efforts in the areas of training, education, and clinical research as Sensus continues to expand its superficial radiation therapy technology for non-invasive skin cancer treatme…
- Novan Awarded Contract by BARDA to Develop a Medical Countermeasure for Thermal Burnshttps://practicaldermatology.com/news/20130829-novan_awarded_contract_by_barda_to_develop_a_medical_countermeasure_for_thermal_burns/2459472/The US Department of Health and Human Services has entered into a contract with Novan to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. The Biomedical Advanced Research and Development Authority (BARDA), an agency within the O…
- FDA Approves Valchlor Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type CTCLhttps://practicaldermatology.com/news/20130826-fda_approves_valchlor_gel_for_the_treatment_of_stage_ia_and_ib_mycosis_fungoides-type_ctcl/2459475/The FDA has granted marketing approval for Ceptaris Therapeutics, Inc.'s orphan drug Valchlor (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. V…
- FDA Approves Mirvaso for Treating Facial Erythema of Rosaceahttps://practicaldermatology.com/news/20130826-fda_approves_mirvaso_for_treating_facial_erythema_of_rosacea/2459476/The FDA recently approved Mirvaso (brimonidine) gel, 0.33% for the topical treatment of the facial erythema of rosacea in adults 18 years of age or older. According to manufacturer Galderma Laboratories, applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 h…
- Iagnosis, Inc., Launches Mobile App for DermatologistOnCall®https://practicaldermatology.com/news/20130815-iagnosis_inc_launches_mobile_app_for_dermatologistoncall/2459479/A new app for an online dermatology platform has recently launched from Iagnosis, Inc. The DermatologistOnCall® app, based on the website www.dermatologistoncall.com, enables to create an account and submit photographs and descriptions of their condition. Patients then receive a response from a boa…
- Merz North America Appoints New Chief Financial Officerhttps://practicaldermatology.com/news/20130807-merz_north_america_appoints_new_chief_financial_officer/2459482/Merz North America has appointed John Donofrio as Chief Financial Officer and Head of Business Development - North America. In this role, Donofrio will be primarily accountable for financial performance, cost management, and strategic business planning and analysis for the Finance organization in N…
- Merz Acquires Neocutis' Skin Care Divisionhttps://practicaldermatology.com/news/20130801-merz_acquires_neocutis/2459486/Merz Pharma Group has acquired the cosmetics, over-the-counter, and prescription skin care businesses of Swiss dermatology company Neocutis. The company's North American division will integrate marketing of Neocutis' line of physician-dispensed topical skin care products in the US. “Neocutis' line…
- Mentor, Medicis Unveiling Joint New Physician Loyalty Programhttps://practicaldermatology.com/news/20130717-mentor_medicis_unveiling_joint_new_physician_loyalty_program/2459494/Mentor Worldwide, LLC and Valeant's Medicis division have entered into a Collaboration Agreement to form a joint physician loyalty program called the M2VP Program (Medicis-Mentor Valued Partner Program), which will include the Mentor line of breast implant products for the aesthetics (non-reimburs…
- Sensus Healthcare Appoints Dr. Clay Cockerell as Medical Directorhttps://practicaldermatology.com/news/20130716-sensus_healthcare_appoints_dr_clay_cockerell_as_medical_director/2459498/Clay Cockerell, MD has been appointed Medical Director for the medical device company Sensus Healthcare. Dr. Cockerell will lead the Medical Advisory Board as the company continues to provide technology for non-invasive skin cancer treatment for non-melanoma skin cancer as well as treatment for kel…